Wei Luo

Dr. Wei Luo

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

17 February 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
FWFlorian Weisel
Florian Weisel
SMSteven J. Mullett
Steven J. Mullett
RERebecca A. Elsner
Rebecca A. Elsner
AMAshley V. Menk
Ashley V. Menk
NTNikita Trivedi
Nikita Trivedi
MSMark J. Shlomchik
Mark J. Shlomchik

15 March 2019 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
MSMark J. Shlomchik
Mark J. Shlomchik
WLWei Luo
Wei Luo
FWFlorian Weisel
Florian Weisel

28 December 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
WLWei Luo
Wei Luo
JAJulia Z. Adamska
Julia Z. Adamska
CLChunfeng Li
Chunfeng Li
RVRohit Verma
Rohit Verma
QLQing Liu
Qing Liu
BPBali Pulendran
Bali Pulendran

30 January 2023 in Nature Materials
Verified
Journal Article
Open access
PDF file
QYQian Yin
Qian Yin
WLWei Luo
Wei Luo
VMVamsee Mallajosyula
Vamsee Mallajosyula
YBYang Bo
Yang Bo
JGJing Guo
Jing Guo
MDMark M Davis
Mark M Davis
The ideal vaccine against viruses such as influenza and SARS-CoV-2 must provide a robust, durable and broad immune protection against multiple viral variants. However, antibody responses to current vaccines often lack robust cross-reactivity. Here we describe a polymeric Toll-like receptor 7 agonist nanoparticle (TLR7-NP) adjuvant, which enhances lymph node targeting, and leads to persistent activation of immune cells and broad immune responses. When mixed with alum-adsorbed antigens, this TLR7-NP adjuvant elicits cross-reactive antibodies for both dominant and subdominant epitopes and antigen-specific CD8+ T-cell responses in mice. This TLR7-NP-adjuvanted influenza subunit vaccine successfully protects mice against viral challenge of a different strain. This strategy also enhances the antibody response to a SARS-CoV-2 subunit vaccine against multiple viral variants that have emerged. Moreover, this TLR7-NP augments antigen-specific responses in human tonsil organoids. Overall, we describe a nanoparticle adjuvant to improve immune responses to viral antigens, with promising implications for developing broadly protective vaccines.

3 February 2023 in Science Immunology
Verified
Journal Article
Closed access
WLWei Luo
Wei Luo
LCLaura Conter
Laura Conter
RERebecca A. Elsner
Rebecca A. Elsner
SSShuchi Smita
Shuchi Smita
FWFlorian Weisel
Florian Weisel
MSMark Shlomchik
Mark Shlomchik
Both B cell receptor (BCR) and CD40 signaling are rewired in germinal center (GC) B cells (GCBCs) to synergistically induce c-MYC and phosphorylated S6 ribosomal protein (p-S6), markers of positive selection. How interleukin-21 (IL-21), a key T follicular helper (T FH )–derived cytokine, affects GCBCs is unclear. Like BCR and CD40 signals, IL-21 receptor (IL-21R) plus CD40 signals also synergize to induce c-MYC and p-S6 in GCBCs. However, IL-21R plus CD40 stimulation differentially affects GCBC fate compared with BCR plus CD40 ligation—engaging unique molecular mechanisms—as revealed by bulk RNA sequencing (RNA-seq), single-cell RNA-seq, and flow cytometry of GCBCs in vitro and in vivo. Whereas both signal pairs induced BLIMP1 in some GCBCs, only the IL-21R/CD40 combination induced IRF4 hi /CD138 + cells, indicative of plasma cell differentiation, along with CCR6 + /CD38 + memory B cell precursors. These findings reveal a second positive selection pathway in GCBCs, document rewired IL-21R signaling in GCBCs, and link specific T FH - and Ag-derived signals to GCBC differentiation.